Arcturus Therapeutics

Arcturus Therapeutics Holdings, Inc. develops pharmaceuticals. It is a clinical-stage mRNA medicines and vaccines company, which focuses on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. The firm's products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Arcturus Therapeutics reports robust earnings and advances in mRNA pipeline

Arcturus Therapeutics delivered strong financial results and showcased progress across key strategic areas
The company's collaborations, advancements in RNA technology, and clinical trial milestones position it for future success
While facing competition and challenges, Arcturus has opportunities to leverage its strengths and drive growth in the mRNA space

Arcturus reports strong Q1 earnings, advances COVID vaccine development

Arcturus Therapeutics demonstrated robust financial performance, progress in COVID-19 vaccine development, and advancements in mRNA therapeutics.
While facing challenges in drug safety and regulatory approvals, the company is well-positioned to capitalize on opportunities for expansion and innovation.
Strategic collaborations and a strong cash position enhance Arcturus' competitive edge and potential for sustained growth in the biopharmaceutical sector.

Arcturus Therapeutics reports Q2 results, advances key programs with CSL

Arcturus Therapeutics showcased financial resilience with a strong cash position and promising program advancements in Q2 2023.
While facing challenges such as high operating expenses and uncertainties in clinical trials, the company is leveraging opportunities for market expansion and program advancement.
Collaboration with CSL and progress on key programs like ARCT-154 and ARCT-810 position Arcturus for continued growth and innovation in the biopharmaceutical space.
Investors can look forward to data releases, program updates, and potential market expansions as Arcturus navigates financial challenges and capitalizes on growth opportunities.

Arcturus Therapeutics excels in Q3 with promising pipeline advancements

Arcturus Therapeutics demonstrated strong financial performance, operational efficiency, and clinical progress in key pipeline candidates, positioning the company for future growth and success.
The company's technological strengths, diverse pipeline, and strategic partnerships underscore its innovation and commitment to addressing unmet medical needs, enhancing market competitiveness.
While facing challenges in regulatory approvals and study outcomes, Arcturus has opportunities to expand its product portfolio, leverage mRNA technology advantages, and drive market growth through strategic planning.
Overall, Arcturus' Q3 earnings call highlights a balanced outlook of financial stability, clinical advancements, and strategic opportunities, signaling a positive trajectory for the company's future.

Arcturus Therapeutics reports mixed financials but strong vaccine pipeline

Arcturus Therapeutics faces financial challenges with expenses exceeding revenues, but maintains a stable cash runway and strong pipeline of vaccine programs
The company's focus on vaccine development for various diseases and mRNA therapeutics showcases promising strengths and diversification in its product offerings
Opportunities in the Japanese market, upcoming Phase II study results, and operational advancements present avenues for growth and value creation for Arcturus

Arcturus reports Q1 results, eyes growth through clinical progress

Arcturus Therapeutics reported mixed financial results in Q1 2024 but remains well-positioned with strong cash reserves and ongoing clinical advancements.
Challenges include managing expenses, revenue variability, and timing uncertainties in future guidance tied to Kostaive revenues.
However, opportunities lie in positive trial outcomes, potential milestone payments, and strategic alignment with global health initiatives.
Overall, Arcturus shows promise in its financial stability, clinical progress, and strategic positioning for future growth and innovation.

Arcturus Therapeutics excels in Q2 2024, poised for mRNA innovation

Arcturus Therapeutics demonstrated strong financial performance and progress in key programs, supported by a solid cash position and strategic collaborations.
While facing challenges such as cost management and regulatory complexities, the company is well-positioned to leverage opportunities in mRNA therapeutics and vaccine development.
Overall, Arcturus shows promise in advancing its pipeline and capturing growth opportunities in the evolving biopharmaceutical landscape.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings' (ARCT) CEO Joseph Payne on Q1 2021 Results - Earnings Call Transcript

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -85.34% and -27.55%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates

Shares of Arcturus Therapeutics (NASDAQ:ARCT) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 220.90% over the past year to ($2.15), which missed the estimate of ($1.25).

Arcturus Therapeutics: Q1 Earnings Insights

SAN DIEGO,--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data

Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Report First Quarter 2021 Financial Results and Provide Corporate Update on May 10, 2021

Arcturus Therapeutics to Report First Quarter 2021 Financial Results and Provide Corporate Update on May 10, 2021

BioNTech SE

CureVac B.V

Probably not, but at least one of them could make you thousands over time.

Could These 3 Brilliant mRNA Stocks Make You Millions?

Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline

Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q4 2020 Results - Earnings Call Transcript

Shares of Arcturus Therapeutics (NASDAQ:ARCT) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 64.47% over the past year to ($1.25), which missed the estimate of ($0.88).

Arcturus Therapeutics: Q4 Earnings Insights

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Positive Clinical Updates

Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Positive Clinical Updates

Earnings Preview: Arcturus Therapeutics (ARCT) Q4 Earnings Expected to Decline

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Report Fourth Quarter and Year-End 2020 Financial Results and Provide Corporate Update on March 1, 2021

Arcturus Therapeutics to Report Fourth Quarter and Year-End 2020 Financial Results and Provide Corporate Update on March 1, 2021

Chesapeake Energy

Fisker Inc

HEXO Corp

Ralph Lauren

Block

Under Armour

With the trading day more than halfway over, the broad markets were trading mixed.

Arcturus Therapeutics, Chesapeake Energy, Square, and More Wednesday Afternoon Analyst Calls

Arcturus (ARCT) is likely to discuss the progress of its COVID-19 vaccine candidate on the fourth-quarter earnings call.

What's in the Cards for Arcturus (ARCT) This Earnings Season?

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #BioCEO--Arcturus Therapeutics to Present at Upcoming Investor Conferences

Arcturus Therapeutics to Present at Upcoming Investor Conferences

Aramark

Hexcel

TAL Education Group

Stocks without sturdy fundamentals are toxic for your portfolio. Identifying such bloated stocks accurately and dumping them at the right time can protect your returns.

Beat Your Portfolio Fatigue by Dumping These Toxic Stocks

Inovio Pharmaceuticals

Vaxart

Probably not, if you're investing for the long term.

Is It Too Late to Buy These 3 COVID Vaccine Latecomer Stocks?

ARCT peaked and then slumped in recent weeks as investors lost interest in its coronavirus vaccine. Promising platform and advantages suggests this is a worthwhile holding.

Arcturus Therapeutics Is A Worthwhile Bet As The Next Blockbuster COVID-19 Vaccine Play

McDonald's

QUALCOMM

Starbucks

Tesla

Baidu

Beyond Meat

Chewy

Darden Restaurants

Roku

With the trading day about half over, the broad markets were pushing higher on Tuesday The S&P 500 and Dow Jones industrial average were both up fractionally, and the Nasdaq posted the largest gain, closer to 1%.

McDonald's, Qualcomm, Starbucks, Tesla and More Tuesday Afternoon Analyst Calls

Only if its COVID-19 vaccine proves to be at least as effective than those developed by its rivals.

Is Arcturus Therapeutics a Buy?

The stock price of Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) increased by over 50% this past week as it went from $46.28 on January 4 morning to $73.58 (as of 10:56 AM ET today). This is why it happened.

ARCT Stock Price Increased Over 50% This Past Week: Why It Happened

One Wall Street analyst is very bullish about the biotech's prospects.

Why Arcturus Therapeutics Stock Skyrocketed Today

Teladoc

Meridian Bioscience

Arcturus Therapeutics (NASDAQ: ARCT) shares are trading higher on Thursday after Wells Fargo initiated coverage on the stock with an Overweight rating. Arcturus Therapeutics is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases.

Why Teladoc Health, Arcturus And Meridian Are Moving Today

FedEx

Lockheed Martin

Albertsons Companies

Big Lots

CME Group

3D Systems

Domino's Pizza

Editas Medicine

Over halfway through the trading day on Thursday, and the broad markets are making a run into the afternoon.

Domino's, FedEx, Lockheed, Roku and More of Tuesday Afternoon's Analyst Calls

The biotech's shares jumped by 299% last year, propelled by optimism about its COVID-19 vaccine candidate.

News for Arcturus Therapeutics Stock (ARCT)